Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros
暂无分享,去创建一个
W. Hiddemann | M. Qumsiyeh | H. Einsele | C. Pott | J. Vardiman | A. Ruppert | M. Dreyling | R. Forstpointner | A. Hänel | R. Repp | B. Metzner | F. Hartmann | H. Böck | H. Wandt | M. Unterhalt | J. Seymour | M. Pettenati | Tanja Lehmann | John F. Seymour | H. Böck | Robert J. Mayer | Richard A. Larson | Maria R. Baer | Yi Ning | R. Stone | Christiane Pott | Roland Repp | Annette Hänel | Frank Hartmann | Hermann Einsele | W. Hiddemann | Andrew J. Carroll | PR Koduru | Sherif S. Farag | K. Archer | Clara D Bloomfield | James W Vardiman
[1] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[2] E. Hoster,et al. The Follicular Lymphoma International Prognostic Index (FLIPI) Predicts Treatment Outcome in Patients with Advanced Stage Follicular Lymphoma Treated Front-Line with Rituximab and the Combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP). , 2005 .
[3] N. Schmitz,et al. Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2005 .
[4] R. Gascoyne,et al. Maintenance Rituximab after CVP Results in Superior Clinical Outcome in Advanced Follicular Lymphoma (FL): Results of the E1496 Phase III Trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. , 2005 .
[5] R. Marcus,et al. Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up. , 2005 .
[6] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Pfreundschuh,et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study , 2005 .
[8] R. Stahel,et al. ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Hainsworth,et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Mendenhall,et al. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[13] P. Solal-Céligny,et al. Follicular lymphoma international prognostic index , 2006, Blood.
[14] E. Kimby,et al. Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial. , 2004 .
[15] G. Salles,et al. Rituximab Added αIFN+CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 Randomized Trial in 359 Patients. , 2004 .
[16] R. Gascoyne,et al. Rituximab-CHOP Versus CHOP with or without Maintenance Rituximab in Patients 60 Years of Age or Older with Diffuse Large B-Cell Lymphoma (DLBCL): An Update. , 2004 .
[17] R. Gascoyne,et al. Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Fonseca,et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. , 2004, Blood.
[19] M. Ghielmini,et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. , 2004, Blood.
[20] J. Hainsworth,et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[22] Pierre Morel,et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[23] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Czuczman,et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] T. Lister,et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] H. Uchino,et al. DEPARTMENT OF INTERNAL MEDICINE , 1966 .